Pedersen and Maggie Fick COPENHAGEN/LONDON (Reuters) -Obesity drugmaker Novo Nordisk cut its sales forecasts on Wednesday for the first time since the launch of its Wegovy weight-loss drug four years ago,

Shares of Novo Nordisk climbed on Wednesday after it said that sales of its blockbuster Wegovy weight loss drug were seen improving in the second half of the year as copycat compounded drugs are phased out.

Novo Nordisk’s oral Wegovy pill for chronic weight loss is under FDA review. If approved, it would be the first oral GLP-1 for obesity.